Back to Search
Start Over
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
- Source :
-
Cancer Chemotherapy & Pharmacology . Aug2018, Vol. 82 Issue 2, p245-250. 6p. - Publication Year :
- 2018
-
Abstract
- <bold>Purpose: </bold>New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy.<bold>Methods: </bold>Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events.<bold>Results: </bold>Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3-4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or anorexia. The peripheral sensory neuropathy rate was 73.3% in the G-nab group and 75% in the FFX group.<bold>Conclusions: </bold>Although G-nab and FFX are effective treatments for advanced pancreatic cancer, the G-nab group had a higher 1-year survival rate, and G-nab can be more safely administered to older patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PACLITAXEL
*PANCREATIC cancer treatment
*MEDICATION safety
*POPULATION aging
*HOSPITAL care
*THERAPEUTIC use of antineoplastic agents
*PANCREATIC tumors
*SURVIVAL
*ALBUMINS
*FOLINIC acid
*RESEARCH
*RESEARCH methodology
*METASTASIS
*DEOXYCYTIDINE
*ANTINEOPLASTIC agents
*RETROSPECTIVE studies
*EVALUATION research
*MEDICAL cooperation
*FLUOROURACIL
*COMPARATIVE studies
*KAPLAN-Meier estimator
Subjects
Details
- Language :
- English
- ISSN :
- 03445704
- Volume :
- 82
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Cancer Chemotherapy & Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 130862706
- Full Text :
- https://doi.org/10.1007/s00280-018-3611-y